Targeting Mitochondrial Dysfunction and Oxidative Stress in Activated Microglia using Dendrimer-Based Therapeutics

Area of Science:

• Neuroscience
• Biomaterials Science
• Pharmacology

Background:

• Mitochondrial oxidative stress is implicated in neurodegenerative diseases, including traumatic brain injury (TBI).
• Current antioxidant delivery methods to mitochondria face challenges in cellular localization, transport, and side effects.
• Innovative strategies are needed for effective mitochondrial targeting in neurodegenerative disease treatment.

Purpose of the Study:

• To develop and evaluate a novel mitochondrial-targeting dendrimer-drug construct for enhanced antioxidant delivery.
• To assess the efficacy of the construct in mitigating oxidative stress in glial cells.
• To confirm the in vivo targeting capabilities in a traumatic brain injury model.

Main Methods:

• Synthesized a hydroxyl polyamidoamine (PAMAM) dendrimer conjugated with triphenyl-phosphonium (TPP) for mitochondrial targeting and N-acetyl cysteine (NAC) as the antioxidant (TPP-D-NAC).
• Assessed in vitro co-localization and mitochondrial uptake in microglia and macrophages using immunohistochemistry.
• Evaluated therapeutic efficacy against oxidative stress in microglia and confirmed in vivo targeting in a rabbit TBI model.

Main Results:

• TPP-conjugated dendrimers showed significantly enhanced co-localization with mitochondria compared to unmodified dendrimers without affecting overall cellular uptake.
• TPP-D-NAC demonstrated superior attenuation of oxidative stress in glial cells compared to unconjugated dendrimer-NAC and free NAC.
• In vivo studies confirmed BBB penetration and specific mitochondrial co-localization in activated microglia and macrophages within the injured hemisphere of TBI rabbits.

Conclusions:

• Mitochondrial targeting via TPP-conjugated dendrimers significantly enhances the therapeutic potential of antioxidants like NAC.
• This approach offers a promising strategy for treating neurodegenerative diseases where oxidative stress and glial cell death are key factors.
• The developed TPP-D-NAC construct shows potential for improved clinical outcomes in TBI and other neurodegenerative conditions.